These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 38795961)

  • 61. The effect of duration and time preference on the gap between adult and child health state valuations in time trade-off.
    Lang Z; Attema AE; Lipman SA
    Eur J Health Econ; 2024 Jun; 25(4):601-613. PubMed ID: 37420133
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Valuing health-related quality of life using a hybrid approach: Tunisian value set for the EQ-5D-3L.
    Chemli J; Drira C; Felfel H; Roudijk B; Al Sayah F; Kouki M; Kooli A; Razgallah Khrouf M
    Qual Life Res; 2021 May; 30(5):1445-1455. PubMed ID: 33447958
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The EQ-5D-3L valuation study for Bermuda: using an on-line EQ-VT protocol.
    Bailey H; Roudijk B; Brathwaite R
    Eur J Health Econ; 2024 Jul; ():. PubMed ID: 38982011
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The EQ-5D-5L Valuation Study in Egypt.
    Al Shabasy SA; Abbassi MM; Finch AP; Baines D; Farid SF
    Pharmacoeconomics; 2021 May; 39(5):549-561. PubMed ID: 33709283
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Preparatory study for the revaluation of the EQ-5D tariff: methodology report.
    Mulhern B; Bansback N; Brazier J; Buckingham K; Cairns J; Devlin N; Dolan P; Hole AR; Kavetsos G; Longworth L; Rowen D; Tsuchiya A
    Health Technol Assess; 2014 Feb; 18(12):vii-xxvi, 1-191. PubMed ID: 24568945
    [TBL] [Abstract][Full Text] [Related]  

  • 66. UK Valuation of EQ-5D-5L, a Generic Measure of Health-Related Quality of Life: A Study Protocol.
    Rowen D; Mukuria C; Bray N; Carlton J; Cooper S; Longworth L; Meads D; O'Neill C; Yang Y
    Value Health; 2023 Nov; 26(11):1625-1635. PubMed ID: 37722593
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Valuation of the EQ-5D-5L in Taiwan.
    Lin HW; Li CI; Lin FJ; Chang JY; Gau CS; Luo N; Pickard AS; Ramos Goñi JM; Tang CH; Hsu CN
    PLoS One; 2018; 13(12):e0209344. PubMed ID: 30586400
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Valuation Survey of EQ-5D-Y Based on the International Common Protocol: Development of a Value Set in Japan.
    Shiroiwa T; Ikeda S; Noto S; Fukuda T; Stolk E
    Med Decis Making; 2021 Jul; 41(5):597-606. PubMed ID: 33754886
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Valuing Health Using Time Trade-Off and Discrete Choice Experiment Methods: Does Dimension Order Impact on Health State Values?
    Mulhern B; Shah K; Janssen MF; Longworth L; Ibbotson R
    Value Health; 2016; 19(2):210-7. PubMed ID: 27021755
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Investigating 5-Level EQ-5D (EQ-5D-5L) Values Based on Preferences of Patients With Heart Disease.
    Gandhi M; Tan RS; Lim SL; Rand K; Lam CSP; Luo N; Cheung YB
    Value Health; 2022 Mar; 25(3):451-460. PubMed ID: 35227458
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Test-Retest Reliability of EQ-5D-5L Valuation Techniques: The Composite Time Trade-Off and Discrete Choice Experiments.
    Purba FD; Hunfeld JAM; Timman R; Iskandarsyah A; Fitriana TS; Sadarjoen SS; Passchier J; Busschbach JJV
    Value Health; 2018 Oct; 21(10):1243-1249. PubMed ID: 30314626
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Determinants of time trade-off valuations for EQ-5D-5L health states: data from the Canadian EQ-5D-5L valuation study.
    Sayah FA; Bansback N; Bryan S; Ohinmaa A; Poissant L; Pullenayegum E; Xie F; Johnson JA
    Qual Life Res; 2016 Jul; 25(7):1679-85. PubMed ID: 26659899
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Assessing the Use of a Feedback Module to Model EQ-5D-5L Health States Values in Hong Kong.
    Wong ELY; Ramos-Goñi JM; Cheung AWL; Wong AYK; Rivero-Arias O
    Patient; 2018 Apr; 11(2):235-247. PubMed ID: 29019161
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Valuation of EQ-5D-3L health states in Singapore: modeling of time trade-off values for 80 empirically observed health states.
    Luo N; Wang P; Thumboo J; Lim YW; Vrijhoef HJ
    Pharmacoeconomics; 2014 May; 32(5):495-507. PubMed ID: 24519603
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Head-to-Head Comparison of EQ-5D-3L and EQ-5D-5L Health Values.
    Selivanova A; Buskens E; Krabbe PFM
    Pharmacoeconomics; 2018 Jun; 36(6):715-725. PubMed ID: 29623559
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Valuation of Quality Weights for EuroQol 5-Dimensional Health States With the Time Trade-Off Method in the Capital of Iran.
    Goudarzi R; Sari AA; Zeraati H; Rashidian A; Mohammad K; Amini S
    Value Health Reg Issues; 2019 May; 18():170-175. PubMed ID: 31096140
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Valuation and Modeling of EQ-5D-5L Health States Using a Hybrid Approach.
    Ramos-Goñi JM; Pinto-Prades JL; Oppe M; Cabasés JM; Serrano-Aguilar P; Rivero-Arias O
    Med Care; 2017 Jul; 55(7):e51-e58. PubMed ID: 25521503
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Valuing EQ-5D-5L health states 'in context' using a discrete choice experiment.
    Cole A; Shah K; Mulhern B; Feng Y; Devlin N
    Eur J Health Econ; 2018 May; 19(4):595-605. PubMed ID: 28569351
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Overview, Update, and Lessons Learned From the International EQ-5D-5L Valuation Work: Version 2 of the EQ-5D-5L Valuation Protocol.
    Stolk E; Ludwig K; Rand K; van Hout B; Ramos-Goñi JM
    Value Health; 2019 Jan; 22(1):23-30. PubMed ID: 30661630
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Valuation of EQ-5D-5L health states: a comparison of seven Asian populations.
    Wang P; Liu GG; Jo MW; Purba FD; Yang Z; Gandhi M; Pattanaphesaj J; Ahn J; Wong EL; Shafie AA; Busschbach JJ; Luo N
    Expert Rev Pharmacoecon Outcomes Res; 2019 Aug; 19(4):445-451. PubMed ID: 30523723
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.